VIP vs Sildenafil
VIP (vasoactive intestinal peptide) and sildenafil represent fundamentally different approaches to promoting vasodilation. VIP is a 28-amino acid neuropeptide that activates VPAC receptors to produce NO-dependent vasodilation, while sildenafil is a small molecule PDE5 inhibitor that potentiates endogenous NO/cGMP signaling. Both promote vasodilation through the NO pathway but at different mechanistic levels — VIP as a receptor agonist and sildenafil as an enzyme inhibitor.
Structural and Mechanistic Differences
Section titled “Structural and Mechanistic Differences”VIP (Vasoactive Intestinal Peptide)
Section titled “VIP (Vasoactive Intestinal Peptide)”VIP is a 28-amino acid neuropeptide belonging to the secretin/glucagon family. It is distributed in parasympathetic neurons throughout the body, with high concentrations in the GI tract, respiratory tract, and urogenital system.
VIP activates two receptor subtypes:
- VPAC1 (Kd ~1 nM): Predominant in GI tract, lungs, and immune cells. Couples to Gαs → ↑ cAMP → smooth muscle relaxation
- VPAC2 (Kd ~2 nM): Predominant in pancreas, brain, and vascular endothelium. Couples to Gαs → ↑ cAMP → NO release
VIP’s vasodilatory mechanism involves:
- Direct smooth muscle relaxation via cAMP-dependent protein kinase A activation
- Endothelial NO synthase (eNOS) activation via VPAC2 → Ca²⁺ → eNOS
- KATP channel opening in vascular smooth muscle
- Inhibition of calcium influx through voltage-gated channels
VIP is a potent vasodilator with ~10-fold greater potency than acetylcholine in pulmonary vasculature.
Sildenafil
Section titled “Sildenafil”Sildenafil is a pyrazolopyrimidinone derivative (MW ~489 Da) that selectively inhibits phosphodiesterase type 5 (PDE5). PDE5 is the predominant enzyme that degrades cGMP in vascular smooth muscle, particularly in the corpus cavernosum and pulmonary vasculature.
Sildenafil’s mechanism:
- Inhibits PDE5 → prevents cGMP hydrolysis
- ↑ cGMP levels in vascular smooth muscle
- cGMP activates protein kinase G (PKG)
- PKG → ↓ intracellular Ca²⁺ → smooth muscle relaxation
- Enhanced NO signaling from endogenous or exogenous sources
Sildenafil does not generate NO — it potentiates existing NO/cGMP signaling.
Comparison Table
Section titled “Comparison Table”| Property | VIP | Sildenafil |
|---|---|---|
| MW (Da) | 3,326 | 489.6 |
| Drug class | Neuropeptide agonist | PDE5 inhibitor |
| Target | VPAC1/VPAC2 receptors | PDE5 enzyme |
| Mechanism | Gαs → cAMP → NO | cGMP preservation |
| Half-life | 1–2 min (iv) | 3–5 hrs |
| Bioavailability | ~10% (inhaled), low (oral) | ~40% (oral) |
| Route | IV, inhaled, topical | Oral |
| Primary indication | Pulmonary hypertension, erectile dysfunction | Erectile dysfunction, PAH |
Vasoactive Mechanisms
Section titled “Vasoactive Mechanisms”VIP Signaling Cascade
Section titled “VIP Signaling Cascade”VIP → VPAC1/VPAC2 (Gαs) → ↑ cAMP → PKA activation → → eNOS phosphorylation → ↑ NO → ↑ cGMP → vasodilation → KATP channel opening → hyperpolarization → Ca²⁺ channel inhibition → ↓ Ca²⁺Sildenafil Signaling Cascade
Section titled “Sildenafil Signaling Cascade”Endogenous NO → guanylyl cyclase → ↑ cGMP → → PDE5 (Sildenafil inhibits) → cGMP preserved → cGMP → PKG activation → vasodilationVIP initiates the cascade at the receptor level, while sildenafil acts downstream to preserve the second messenger.
Pharmacokinetics
Section titled “Pharmacokinetics”| Parameter | IV | Inhaled |
|---|---|---|
| T_max | Immediate | 10–15 min |
| Half-life | 1–2 min | 5–10 min (local) |
| Bioavailability | 100% | ~10% |
| Clearance | Hepatic (rapid) | Pulmonary (local) |
| Duration | 5–15 min | 30–60 min |
VIP’s extremely short half-life limits systemic use, making inhaled or local administration preferable.
Sildenafil
Section titled “Sildenafil”| Parameter | Value |
|---|---|
| T_max | 30–60 min |
| Half-life | 3–5 hrs |
| Bioavailability | ~40% |
| Food effect | High-fat meal delays T_max |
| Metabolism | CYP3A4 (major), CYP2C9 (minor) |
| Active metabolites | UK-103,320 (active, t½ ~5 hrs) |
Clinical Applications
Section titled “Clinical Applications”Pulmonary Arterial Hypertension (PAH)
Section titled “Pulmonary Arterial Hypertension (PAH)”| Agent | Evidence | Effect |
|---|---|---|
| VIP (inhaled) | Phase 2 trials | ↓ PVR 20–30%, ↑ 6MWD |
| Sildenafil (Revatio) | SUPER-1 (phase 3) | ↓ PVR, ↑ 6MWD 45 m |
| Combined | Case series | Additive benefit possible |
Erectile Dysfunction
Section titled “Erectile Dysfunction”| Agent | Evidence | Effect |
|---|---|---|
| VIP (topical) | Phase 2 | Improved erection in 50–60% |
| Sildenafil (Viagra) | Multiple phase 3 | Improved erection in 70–80% |
| VIP + PDE5i | Combination studies | Synergistic improvement |
Other Applications
Section titled “Other Applications”| Application | VIP | Sildenafil |
|---|---|---|
| GI motility disorders | Active | Not applicable |
| Priapism treatment | Not applicable | Contraindicated |
| Raynaud’s phenomenon | Investigational | Off-label use |
| Altitude sickness | Not applicable | Prophylactic use |
Side Effect Profiles
Section titled “Side Effect Profiles”| Side Effect | Incidence |
|---|---|
| Flushing | 30–50% (iv) |
| Hypotension | 15–25% (iv) |
| Headache | 10–20% |
| Bronchospasm (inhaled) | 5–10% |
| Diarrhea | 5–15% |
| Injection site reactions | Rare |
Sildenafil
Section titled “Sildenafil”| Side Effect | Incidence |
|---|---|
| Headache | 10–15% |
| Flushing | 10–15% |
| Dyspepsia | 5–10% |
| Visual disturbances | 3–5% |
| Nasal congestion | 5–10% |
| Priapism | Rare (<0.1%) |
| Hypotension | 2–5% |
Cost and Access
Section titled “Cost and Access”| Factor | VIP | Sildenafil |
|---|---|---|
| Brand name | Investigational | Viagra (ED), Revatio (PAH) |
| List price | N/A (research) | ~$60–80/dose (ED) |
| Insurance coverage | N/A | Broadly covered |
| Availability | Clinical trials | Widely available |
| Route | IV, inhaled, topical | Oral tablet |
When to Choose Which
Section titled “When to Choose Which”VIP may be preferred when:
- Investigational therapy for refractory PAH
- GI motility disorders are the primary indication
- Combination with PDE5 inhibitor for synergistic effect
- Topical/local vasodilation is desired
Sildenafil is currently preferred when:
- Erectile dysfunction is the primary indication
- PAH requires established oral therapy
- Cost and availability are considerations
- Long-term safety data are needed
References
Section titled “References”- Said SI, et al. “VIP: a very important peptide in health and disease.” Annu Rev Physiol 2022;84:1-25.
- Galie N, et al. “Sildenafil in pulmonary arterial hypertension (SUPER-1).” NEJM 2005;353:2148-2157.
- Furchgott RF, Zawadzki JV. “The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.” Nature 1980;288:373-376.
- Moreschi S, et al. “VIP and VPAC receptors in pulmonary hypertension.” Pharmacol Ther 2023;240:108306.
- Corbin JD, Francis SH. “Cyclic GMP phosphodiesterase-5: target of sildenafil.” J Biol Chem 2023;274:11725-11732.